The company's shares are GMP Priced at Rs 290 on the gray market, the stock is expected to be listed at a premium of over 60% considering the upper price band of Rs 490.
Prior to the issue, the company had raised approximately Rs 549 million from. anchor investors.
Some of the leading investors who participated in the anchor round include: capital group, Fidelity Investments, Loomis Sayles and Company, Jupiter Asset Management, Abu Dhabi Investment Authority, SBI Investment TrustICICI Prudential Mutual Fund etc.
The IPO consisted of an issue of fresh shares worth up to Rs 750 million and an offer for sale (OFS) of up to 2.93 billion shares by existing investors. Under OFS, Manish Gupta, Rajesh Bhaskaran Nehru, Anita Nehru, Carlyle and Brighton Park Capital were inducted. , Nadatur Family Office and others sold stakes. The proceeds raised through the new offering will be used to pay down debt, fund capital expenditures, pay deferred consideration for one of our prior acquisitions, fund inorganic growth, and for general corporate purposes.analysts believe Indegene IPO Offering investors a unique opportunity to invest in a leading provider of digitally-driven commercialization services customized for the life sciences industry
Founded in 1998, Indegene provides solutions that enable biopharmaceutical, emerging biotechnology, and medical device companies to develop products, bring them to market, and drive sales throughout their lifecycles.
The company combines more than 20 years of healthcare expertise with our technology platform to help life sciences companies with clinical trials, support regulatory and safety operations, help bring products to market, and support sales and We provide solutions that promote marketing. Product life cycle.
For the fiscal year ending December 2023, the company posted operating revenue of 1,969 million rupees and post-tax profit of 241 million rupees.
Kotak Mahindra Capital, Citigroup Global Markets India, JP Morgan India and Nomura Financial Advisory & Securities (India) are the bookrunning bookrunners for the issue.
(Disclaimer: Recommendations, suggestions, views and opinions given by experts are their own. They do not represent the views of Economic Times)